309 related articles for article (PubMed ID: 6127401)
1. Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist.
Hahn RA; Wardell JR; Sarau HM; Ridley PT
J Pharmacol Exp Ther; 1982 Nov; 223(2):305-13. PubMed ID: 6127401
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effects of the novel inotropic agent, ibopamine, with epinine, dopamine and fenoldopam on renal vascular dopamine receptors in the anesthetized dog.
Nichols AJ; Smith JM; Shebuski RJ; Ruffolo RR
J Pharmacol Exp Ther; 1987 Aug; 242(2):573-8. PubMed ID: 2886644
[TBL] [Abstract][Full Text] [Related]
3. SK&F 87516, a close analog of fenoldopam, is a partial agonist at dopamine-1 and alpha-2 receptors and produces stimulation of 5-hydroxytryptamine-2 receptors in the cardiovascular system of the rat.
Le Monnier de Gouville AC; Lawson K; Thiry C; Cavero I
J Pharmacol Exp Ther; 1991 Mar; 256(3):1049-56. PubMed ID: 1672375
[TBL] [Abstract][Full Text] [Related]
4. Further characterization of the cardiovascular effects of the dopamine beta-hydroxylase inhibitor SK&F 102698 in conscious hypertensive rats.
Ohlstein EH; Kruse LI; Ezekiel M; Willette RN
J Pharmacol Exp Ther; 1988 Oct; 247(1):186-95. PubMed ID: 3050029
[TBL] [Abstract][Full Text] [Related]
5. Identification of fenoldopam prodrugs with prolonged renal vasodilator activity.
Brooks DP; DePalma PD; Cyronak MJ; Bryant MA; Karpinski K; Mico B; Gaitanopoulos DE; Chambers PA; Erhard KF; Weinstock J
J Pharmacol Exp Ther; 1990 Sep; 254(3):1084-9. PubMed ID: 1975620
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the hemodynamic activities of fenoldopam and its enantiomers in the dog.
Kinter LB; Horner E; Mann WA; Weinstock J; Ruffolo RR
Chirality; 1990; 2(4):219-25. PubMed ID: 1982058
[TBL] [Abstract][Full Text] [Related]
7. Effects of fenoldopam on regional vascular resistance in conscious spontaneously hypertensive rats.
Lappe RW; Todt JA; Wendt RL
J Pharmacol Exp Ther; 1986 Jan; 236(1):187-91. PubMed ID: 2867214
[TBL] [Abstract][Full Text] [Related]
8. Suppression of sympathetic ganglionic neurotransmission by the selective dopamine-1 receptor agonist fenoldopam (SK&F 82526) in the anesthetized dog.
Shebuski RJ; Fujita T; Smith JM; Kopaciewicz LJ; Blumberg AL; Hieble JP
J Pharmacol Exp Ther; 1985 Dec; 235(3):735-40. PubMed ID: 2867207
[TBL] [Abstract][Full Text] [Related]
9. Potential usefulness of renal vasodilators in hypertension and renal disease: SK&F 82526.
Ackerman DM; Blumberg AL; McCafferty JP; Sherman SS; Weinstock J; Kaiser C; Berkowitz B
Fed Proc; 1983 Feb; 42(2):186-90. PubMed ID: 6130004
[TBL] [Abstract][Full Text] [Related]
10. Systemic, pulmonary and coronary haemodynamic actions of the novel dopamine receptor agonist in awake pigs at rest and during treadmill exercise Z1046.
Duncker DJ; Haitsma DB; van der Geest IE; Stubenitsky R; van Meegen JR; Man in't Veld AJ; Verdouw PD
Br J Pharmacol; 1997 Mar; 120(6):1101-13. PubMed ID: 9134223
[TBL] [Abstract][Full Text] [Related]
11. Effects of cerebroventricular administration of ouabain on renal hemodynamics in anesthetized dogs: evidence for the participation of renal dopaminergic vasodilator fibers.
Hom GJ; Jandhyala BS
J Pharmacol Exp Ther; 1984 Aug; 230(2):275-83. PubMed ID: 6747837
[TBL] [Abstract][Full Text] [Related]
12. SK&F 83822 distinguishes adenylyl cyclase from phospholipase C-coupled dopamine D1-like receptors: behavioural topography.
O'Sullivan GJ; Roth BL; Kinsella A; Waddington JL
Eur J Pharmacol; 2004 Feb; 486(3):273-80. PubMed ID: 14985049
[TBL] [Abstract][Full Text] [Related]
13. Studies on vascular dopamine receptors with the dopamine receptor agonist: SK&F 82526.
Ohlstein EH; Zabko-Potapovich B; Berkowitz BA
J Pharmacol Exp Ther; 1984 May; 229(2):433-9. PubMed ID: 6143817
[TBL] [Abstract][Full Text] [Related]
14. Effects of catechol ring fluorination on cardiovascular and renal activities of fenoldopam enantiomers.
Kinter LB; Mann WA; Weinstock J; Ruffolo RR
Chirality; 1994; 6(5):446-55. PubMed ID: 7915128
[TBL] [Abstract][Full Text] [Related]
15. Topographical resolution of jaw movements mediated by cyclase- vs. non-cyclase-coupled dopamine D(1)-like receptors: studies with SK&F 83822.
Fujita S; Lee J; Kiguchi M; Uchida T; Cools AR; Waddington JL; Koshikawa N
Eur J Pharmacol; 2006 May; 538(1-3):94-100. PubMed ID: 16682023
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the effects of dopamine-1 and dopamine-2 receptor agonists on coronary flow.
Zhao RR; Wang PH; Zhang WF; Fennell WH
Methods Find Exp Clin Pharmacol; 1992; 14(1):5-11. PubMed ID: 1352371
[TBL] [Abstract][Full Text] [Related]
17. Effects of SK&F 82526 and SK&F 83742 on the renal vascular dopamine receptor.
Schmidt M; Imbs JL; Giesen-Crouse EM; Schwartz J
J Pharmacol; 1985; 16(1):15-22. PubMed ID: 2582206
[TBL] [Abstract][Full Text] [Related]
18. Hypotensive and regional hemodynamic effects of the dopamine receptor agonist SK & F 85174 in the anesthetized rat.
Van der Niepen P; Schoors DF; Dupont AG
Arch Int Pharmacodyn Ther; 1991; 313():98-107. PubMed ID: 1687774
[TBL] [Abstract][Full Text] [Related]
19. The cardiovascular actions of dopamine and the effects of central and peripheral catecholaminergic receptor blocking drugs.
Setler PE; Pendleton RG; Finlay E
J Pharmacol Exp Ther; 1975 Mar; 192(3):702-12. PubMed ID: 1120964
[TBL] [Abstract][Full Text] [Related]
20. Effects of dopamine on renal haemodynamics tubular function and sodium excretion in normal humans.
Olsen NV
Dan Med Bull; 1998 Jun; 45(3):282-97. PubMed ID: 9675540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
